Tetrabenazine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Tetrabenazine

Tetrabenazine (marketed under the trade names Nitoman® in Canada and Xenazine® in New Zealand and some parts of Europe - also available in the USA as an orphan drug) is a dopamine-depleting drug that is closely related to the antipsychotics and works similarly, though its action is subtly different and it is not necessarily considered an antipsychotic itself. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Common uses

Tetrabenazine is used as a treatment, but not a cure for hyperkinetic movement disorders such as:

  • Huntington's Disease - specificially the chorea associated with it
  • Tourette's Syndrome and other tic disorders
  • Tardive dyskinesia, a serious and sometimes irreversible side effect of long-term use of many antipsychotics, mainly typical antipsychotics

Side Effects

Because tetrabenazine is closely related to the antipsychotics, many of its side effects are similar. Some of these include:

  • Depression - the most common side effect, reported in roughly 15% of those who take the medication
  • Dizziness/drowsiness
  • Akathisia (aka "restless pacing" - an inability to keep still, with intense anxiety when forced to do so)

Unlike many of the antipychotics, tetrabenazine is not known to cause Tardive dyskinesia, and in fact can be an effective treatment for the antipsychotic-induced movement disorder.

Warnings

  • Because of the relatively high incidence of depression, it has been recommended that people with a history of depression avoid taking tetrabenazine. Research into this is ongoing however, and this warning may be dropped in the future.

Read more at Wikipedia.org


[List your site here Free!]


Prestwick Pharmaceuticals Launches NITOMAN -Tetrabenazine- Patient Support Program in Canada; Drug Reimbursement and Pharmacist Support Services Provided
From Business Wire, 3/18/05

DUNDAS, Ontario -- Prestwick Pharmaceuticals Inc., a CNS specialty pharmaceutical company, announced today the planned launch of the NITOMAN(R) Access Hotline in Canada, a free telephone support service established to help patients suffering from hyperkinetic movement disorders to explore reimbursement options and obtain disease and treatment support in relation to NITOMAN therapy.

NITOMAN, a dopamine depletor that works by selectively blocking vesicular monoamine transporter 2 (VMAT2), is the only product approved in Canada for the treatment of a series of hyperkinetic movement disorders, including chorea associated with Huntington's Disease, tardive dyskinesia and Tourette's syndrome. Approximately 50,000 Canadians suffer from these disorders, which are characterized by excessive, involuntary and repetitive movements, which may involve the face, limbs or the entire body.

Through the program, eligible patients will receive a free supply of NITOMAN for six weeks. All patients will receive reimbursement assistance, if required, which will include insurance benefits and coverage verification, and prior authorization assistance.

Patient support services will include scheduled phone calls from registered pharmacists to encourage compliance with the prescribed dosing regimen and to discuss the potential side effects of therapy. Additionally, to help ensure that patients receive optimal benefit from treatment, pharmacists will collect information on dosing and treatment experience for feedback to patients' physicians.

Patients or their physicians who are interested in initiating the reimbursement assessment process should call the NITOMAN Access Hotline at 1-888-NITOMAN (1-888-648-6626). NITOMAN therapy will be provided to qualified Canadian patients who are in the process of obtaining either public or private coverage, and meet the approved indication for NITOMAN as well as the coverage criteria from public/private payors.

Tetrabenazine

In 2004, Prestwick Pharmaceuticals acquired the rights from Cambridge Laboratories Ltd., UK, to commercialize tetrabenazine in Canada under the brand name NITOMAN. Tetrabenazine is available in some European markets and New Zealand as XENAZINE(R). Tetrabenazine can have a profound effect on chorea, with many patients demonstrating marked to good improvement. Side effects can include drowsiness, insomnia, akathisia and depression.

Prestwick Pharmaceuticals

Prestwick Pharmaceuticals, Inc., is an emerging specialty pharmaceutical company that focuses on treatments for CNS disorders. The company has multiple product candidates in clinical development for Huntington's Disease, Parkinson's disease and schizophrenia. The company anticipates filing a New Drug Application (NDA) for tetrabenazine with the U.S. Food and Drug Administration (FDA) in the near future. Prestwick was granted both fast track and orphan designation by the FDA for tetrabenazine as a therapy for chorea associated with Huntington's Disease.

COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group

Return to Tetrabenazine
Home Contact Resources Exchange Links ebay